US Patent Issued to Regeneron Pharmaceuticals on March 17 for "Anti-CD3 antibodies with low binding affinity" (New York, New Jersey Inventors)

ALEXANDRIA, Va., March 17 -- United States Patent no. 12,577,304, issued on March 17, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Anti-CD3 antibodies with low binding affinity" was invented by Eric Smith (New York), Lauric Haber (Rye Brook, N.Y.), Robert Babb (River Edge, N.J.), Gang Chen (Yorktown Heights, N.Y.) and Douglas MacDonald (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides antibodies that bind to CD3 with weak or no detectable binding affinity and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with low affinity and induce human T cell proliferation and hence induce T cell-media...